Phase 2 N=27 A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
Alzheimer Disease · Mild Cognitive Impairment
Primary: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake — 0.00; 0.10; 0.12 SUVR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=69 A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
Cystic Fibrosis
Primary: Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 — -35.0 milligrams per deciliter (mg/dl)
Phase 1 N=8 Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
N/A N=55,759 Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
Venous Thromboembolism
Primary: Number of Participants With Interruption in Index Anticoagulant Treatment — 3429; 8169; 965; 492 Participants
Phase 3 N=167 Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
Breast Cancer · Sentinel Lymph Node · Breast Neoplasms
Primary: Median Post-Procedural Pain Score — 2; 2; 4; 4 score on a scale
Phase 2 N=30 Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Renal Cell Carcinoma
Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs
Phase 3 N=194 Safety and Efficacy of Emixustat in Stargardt Disease
Stargardt Disease
Primary: Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF) — 1.280; 1.309 Rate of change from BL (mm^2/yr)
Phase 1 N=45 Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
RSV Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants
N/A N=41 CGM Use in Children With Type 2 Diabetes
Type 2 Diabetes · Hyperglycemia Due to Type 2 Diabetes Mellitus
Primary: Percentage of Time in Range Glucose Control — 49.2; 50.7 percentage of time in target range
N/A N=14 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Schizophrenia
Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)
N/A N=10 Empower Opioid Misuse & Chronic Pain
Chronic Pain · Opioid Use
Primary: Pain Intensity Score Measures — 55; 57 Score on a scale
N/A N=10 Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Real-time Electrogram Morphology Recurrence (EMR) Mapping Feasibility — 10 Participants
Phase 3 N=544 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa
Primary: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) — 42.3; 46.1; 31.2 Percentage of Participants — p=0.0149
N/A N=47 TMS Augmented Exposure Therapy
Phobia
Primary: Subjective Anxiety Symptoms — 17.4; 7.3 units on a scale — p=0.025
N/A N=41 Exercise Dosing for Pain in Healthy Participants
Pain
Primary: Intervention Effects on Mechanical Sensitivity Threshold — 125.6; 93.56; 63.04; 70.27 100*Value at 24 hours/Value at Baseline